TY - JOUR
T1 - Short-term exposure to desert dust and the risk of acute myocardial infarction in Japan
T2 - a time-stratified case-crossover study
AU - JROAD Investigators
AU - Ishii, Masanobu
AU - Seki, Tomotsugu
AU - Kaikita, Koichi
AU - Sakamoto, Kenji
AU - Nakai, Michikazu
AU - Sumita, Yoko
AU - Nishimura, Kunihiro
AU - Miyamoto, Yoshihiro
AU - Noguchi, Teruo
AU - Yasuda, Satoshi
AU - Tsutsui, Hiroyuki
AU - Komuro, Issei
AU - Saito, Yoshihiko
AU - Ogawa, Hisao
AU - Tsujita, Kenichi
AU - Kawakami, Koji
N1 - Funding Information:
This work was supported by Scholarship from the Minister of Education, Science, Sports and Culture, who entrusts the head with the management of accounts, and Japan Society for the Promotion of Science (JP19K17531).
Funding Information:
All authors declare no potential conflict of interest in connection with this paper and have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Dr. Seki reports personal fees from Pfizer.inc., outside the submitted work. Dr. Kaikita reports grants and other from Bayer Yakuhin, Ltd., grants and other from Daiichi Sankyo Co., Ltd., grants from Novartis Pharma K.K., grants from SBI pharma K.K., from null, outside the submitted work. Dr. Sakamoto reports grants from Daiichi-Sankyo Co., Ltd., outside the submitted work. Dr. Yasuda reports grant support from Takeda and Abbott, and lecture fees from Daiichi Sankyo and Bristol-Myers Squibb. Dr. Saito reports grants and personal fees from Bayer Holding Ltd, grants from Terumo Corporation, grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Amgen Astellas BioPharma K.K., grants and personal fees from Novartis Pharma K.K., grants and personal fees from Ono Pharmatical Co., Ltd, grants and personal fees from Shionogi & Co., Ltd, grants and personal fees from Teijin Pharma Ltd., grants from St. Jude Medical Japan Co., Ltd., grants and personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Astellas Pharma Inc., personal fees from Asahi Kasei Pharma Corporation, personal fees from Actelion Pharmaceuticals Japan Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from Dainippon Sumitomo Pharma Co., Ltd., personal fees from Eisai Co., Ltd., personal fees from Fuji Yakuhin Co., Ltd., personal fees from Kowa Pharmaceutical Co., Ltd, personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Medtronic, Inc., personal fees from MSD K.K. a subsidiary of Merck & Co., Inc., personal fees from Nihon Medi-Physics Co.,Ltd., personal fees from Sanofi K.K., personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from ZERIA Pharmaceutical Co., Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Pfizer Japan Inc., personal fees from Taisho Toyama Pharmaceutical Co., Ltd., personal fees from Toa Eiyo LTD., outside the submitted work. Dr. Tsutsui reports personal fees from Novartis Pharma K.K., personal fees from Pfizer Japan Inc., personal fees from Bayer Yakuhin, Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from MSD K.K., personal fees from Mitsubishi Tanabe Pharm Corp., personal fees from Teijin Pharm Ltd., personal fees from Bristol-Myers Squibb Company, personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Otsuka Pharmaceuticals Co., Ltd., personal fees from Astellas Parma Inc., outside the submitted work. Dr. Komuro reports grants from Otsuka Pharmaceuticals Co., Ltd., grants and personal fees from Daiichi Sankyo Co., Ltd., grants from Dainippon Sumitomo Pharma Co., Ltd., grants and personal fees from Takeda Pharmaceutical Co., Ltd., grants from Teijin Pharm Ltd., grants from Toa Eiyo LTD., personal fees from Astellas Pharma Inc., personal fees from AstraZeneca K.K., personal fees from MSD K.K., personal fees from Ono Pharmatical Co., Ltd, personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Bayer Yakuhin, Ltd., personal fees from Pfizer Japan Inc., outside the submitted work; Dr. Tsujita reports personal fees from Novartis Pharma K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from MSD K.K., personal fees from Mitsubishi Tanabe Pharm Corp., grants from Teijin Pharm Ltd., personal fees from Bristol-Myers Squibb Company, personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Otsuka Pharmaceuticals Co., Ltd., personal fees from Astellas Parma Inc., grants from AstraZeneca K.K., personal fees from Sanofi K.K., personal fees from Cardinal Health Japan Inc., personal fees from Goodman Co.,LTD., personal fees from Chugai Pharmaceutical Co, Ltd., personal fees from Boston Scientific Japan K.K., personal fees from Kowa Pharmaceutical Co. Ltd., personal fees from Pfizer Japan Inc., personal fees from Shionogi & Co., outside the submitted work. Dr. Kawakami reports personal fees from Shin Nippon Biomedical Laboratories, Ltd., other from School Health Record Center Co.,Ltd., other from Real World Data, Co., Ltd., grants from Olympus Corporation, grants from Bayer Yakuhin, Ltd., grants from Cmic Co., Ltd., grants from Novartis Pharma K.K., grants from Suntory Beverage & Food Limited, grants from Sumitomo Dainippon Pharma Co., Ltd., grants from Medical Platform Co. Ltd., grants from STELLA PHARMA CORPORATION, grants from Amgen Astellas BioPharma K.K., outside the submitted work. Other authors declare no potential conflict of interest.
Publisher Copyright:
© 2020, Springer Nature B.V.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Particulate matter from natural sources such as desert dust causes harmful effects for health. Asian dust (AD) increases the risk of acute myocardial infarction (AMI). However, little is known about the risk of myocardial infarction with nonobstructive coronary arteries (MINOCA), compared to myocardial infarction with coronary artery disease (MI-CAD). Using a time-stratified case-crossover design and conditional logistic regression models, the association between short-term exposure to AD whereby decreased visibility (< 10 km) observed at each monitoring station nearest to the hospitals was used for exposure measurements and admission for AMI in the spring was investigated using a nationwide administrative database between April 2012 and March 2016. According to presence of revascularization and coronary atherosclerosis, AMI patients (n = 30,435) were divided into 2 subtypes: MI-CAD (n = 27,202) or MINOCA (n = 3233). The single lag day-2 was used in AD exposure based on the lag effect analysis. The average level of meteorological variables and co-pollutants on the 3 days prior to the case/control days were used as covariates. The occurrence of AD events 2 days before the admission was associated with admission for MINOCA after adjustment for meteorological variables [odds ratio 1.65; 95% confidence interval (CI) 1.18–2.29], while the association was not observed in MI-CAD. The absolute risk difference of MINOCA admission was 1.79 (95% CI 1.21–2.38) per 100,000 person-year. These associations between AD exposure and the admission for MINOCA remained unchanged in two-pollutant models. This study provides evidence that short-term exposure to AD is associated with a higher risk of MINOCA, but not MI-CAD.
AB - Particulate matter from natural sources such as desert dust causes harmful effects for health. Asian dust (AD) increases the risk of acute myocardial infarction (AMI). However, little is known about the risk of myocardial infarction with nonobstructive coronary arteries (MINOCA), compared to myocardial infarction with coronary artery disease (MI-CAD). Using a time-stratified case-crossover design and conditional logistic regression models, the association between short-term exposure to AD whereby decreased visibility (< 10 km) observed at each monitoring station nearest to the hospitals was used for exposure measurements and admission for AMI in the spring was investigated using a nationwide administrative database between April 2012 and March 2016. According to presence of revascularization and coronary atherosclerosis, AMI patients (n = 30,435) were divided into 2 subtypes: MI-CAD (n = 27,202) or MINOCA (n = 3233). The single lag day-2 was used in AD exposure based on the lag effect analysis. The average level of meteorological variables and co-pollutants on the 3 days prior to the case/control days were used as covariates. The occurrence of AD events 2 days before the admission was associated with admission for MINOCA after adjustment for meteorological variables [odds ratio 1.65; 95% confidence interval (CI) 1.18–2.29], while the association was not observed in MI-CAD. The absolute risk difference of MINOCA admission was 1.79 (95% CI 1.21–2.38) per 100,000 person-year. These associations between AD exposure and the admission for MINOCA remained unchanged in two-pollutant models. This study provides evidence that short-term exposure to AD is associated with a higher risk of MINOCA, but not MI-CAD.
UR - http://www.scopus.com/inward/record.url?scp=85078625240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078625240&partnerID=8YFLogxK
U2 - 10.1007/s10654-020-00601-y
DO - 10.1007/s10654-020-00601-y
M3 - Article
C2 - 31950372
AN - SCOPUS:85078625240
VL - 35
SP - 455
EP - 464
JO - European Journal of Epidemiology
JF - European Journal of Epidemiology
SN - 0393-2990
IS - 5
ER -